EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSMLUG00000011706
Gene Symbol: GRIN3B
2 Cross references
286 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSMLUG00000008425
Gene Symbol: GRIK2
2 Cross references
331 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSMLUG00000003400
Gene Symbol: GRIK3
4 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSMLUG00000015614
Gene Symbol: GRIK4
2 Cross references
260 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSMLUG00000014661
Gene Symbol: GRIK5
2 Cross references
302 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSMLUG00000004621
Gene Symbol: GRM2
2 Cross references
276 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSMLUG00000016200
Gene Symbol: GRM5
2 Cross references
272 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2c-Like

Ensembl ID : ENSMLUG00000017779
Gene Symbol: LOC102430009
3 Cross references
244 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSMLUG00000025775
Gene Symbol: LOC102418872
3 Cross references
278 Possible Orthologues:

Glutathione S-Transferase Pi 1

Ensembl ID : ENSMLUG00000011529
Gene Symbol: GSTP1
4 Cross references
172 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSMLUG00000016622
Gene Symbol: GSK3A
2 Cross references
260 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSMLUG00000002885
Gene Symbol: GSK3B
2 Cross references
241 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).